Unfortunately, the aaRS inhibitors that have to date reached clinical trials are subject to 3 rapid resistance development through mutation, a phenomenon that limits their potential 4 clinical utility. Here we confirm the intuitively correct idea that simultaneous targeting of two 5 different aaRS enzymes prevents the emergence of spontaneous bacterial resistance at high 6 frequency, a finding that supports the development of multi-targeted anti-aaRS therapies. 7
Text 8
The aminoacyl-tRNA synthetase (aaRS) family of enzymes possess several features that 9 render them promising prospects as broad-spectrum antibacterial drug targets; they are 10 essential for viability, found in all bacterial pathogens, and are in many cases sufficiently 11 structurally distinct from their eukaryotic counterparts to allow selective targeting (1, 2). 12
Furthermore, there exists both chemical and clinical validation for these enzymes as useful 13 targets for antibacterial chemotherapy (1). However, despite the potential promise of this 14 family of targets, only a single aaRS inhibitor with a relatively limited indication has to date 15 been approved for the management of bacterial infection; mupirocin, an inhibitor of 16 isoleucyl-tRNA synthetase, is a topical agent deployed for nasal decolonization of 17
Staphylococcus aureus and for the treatment of superficial skin infection (3).
18
Unfortunately, in common with other antibacterial agents that act upon a single enzyme 19 target, aaRS inhibitors possess an intrinsic resistance liability (4). Mutants resistant to aaRS 20 inhibitors are selected at high frequency in bacterial populations (~10 -7 ), typically as a result 21 of point mutations within the gene encoding the drug target that lead to alteration of the 22 latter in a manner that negatively impacts inhibitor binding (1). This liability, whilst 23 manageable in the context of aaRS inhibitors such as mupirocin that are applied topically at 24 concentrations sufficiently high to prevent or mitigate resistance, presents a definite 25 problem for the development of aaRS inhibitors for systemic treatment of more serious 26 bacterial disease. Indeed, GSK halted Phase II clinical trials of the leucyl-tRNA synthetase 27 inhibitor GSK2251052 for the treatment of complicated urinary tract infection in adults 28 following the emergence of mutants of Escherichia coli resistant to the drug in 3 of 14 29 patients within two days of administration (5). 30
It has been proposed that the resistance liabilities associated with aaRS inhibitors could be 31 overcome with an inhibitor capable of targeting two or more aaRS enzymes simultaneously 32
(1, 2, 6); an equivalent effect could be achieved with a cocktail of two or more aaRS 33 inhibitors delivered in combination. This proposal is supported by the multi-target 34 hypothesis, which states that antibacterial agents for which resistance is not readily selected 35 by mutation usually act on more than one cellular target (7). By simultaneously targeting 36 two or more aaRS enzymes, a situation is created in which the likelihood of resistance 37 arising as a consequence of mutation in multiple targets becomes extremely low; for two 38 aaRS enzymes, the frequency of mutation to resistance would be predicted to drop to ~10 -14
39
(~10 -7 x ~10 -7 ). Whilst this idea seems intuitively correct, it is possible to conceive of 40 reasons why it might not hold true (e.g. a single mutation at a site other than the target 41 genes could confer resistance to inhibition of multiple aaRS enzymes), and it has to our 42 knowledge not been tested. Here, we sought to evaluate the potential utility of such an 43 approach by studying the in vitro emergence of resistance to combinations of aaRS 44 inhibitors in Staphylococcus aureus.
45
The antibacterial aaRS inhibitors used in this study were mupirocin (MUP; Sigma-Aldrich, 46
Poole, UK), GSK2251052 (GSK) which was synthesised as described (8, 9) , and the 47 methionyl-tRNA synthetase inhibitor, REP8839 (REP; Axon Medchem, Groningen, 48 Netherlands). Minimum inhibitory concentrations (MIC) of each compound for S. aureus 49 SH1000 (10, 11) were determined by broth microdilution in Mueller Hinton II (MHII) 50 following CLSI guidelines (12), and the frequency at which mutants resistant to each 51 individual compound arose was measured at 4XMIC on MHII agar, essentially as described 52 (13). MUP, REP and GSK inhibited growth of S. aureus SH1000 at concentrations of 0.25, 53 0.125 and 4 g/ml, respectively, and at 4XMIC, all three compounds selected resistant 54 mutants at frequencies of 10 -7 -10 -8 (Table 1) . For MUP and REP, these frequencies are 55 comparable to those previously reported for S. aureus (14, 15); for GSK, mutation 56 frequencies to resistance have not been reported for S. aureus, but the values obtained here 57 are comparable to those reported for E. coli (5). To confirm that colonies recovered on agar 58 containing these agents at 4XMIC were indeed mutants exhibiting reduced susceptibility to 59 the corresponding aaRS inhibitor (not 'break-through' growth), they were subjected to MIC 60 determinations and PCR amplification/DNA sequencing of the gene encoding the drug target 61 (ileS, metRS and leuS in strains selected with MUP, REP and GSK, respectively). All colonies Whilst a dual-targeted aaRS inhibitor/ inhibitor combination would therefore overcome the 84 gross resistance liability associated with single-target aaRS inhibitors, it seems likely that 85 resistance would nonetheless arise over time by step-wise accumulation of resistance 86 mutations as has been observed for other multi-targeted antibacterials (e.g. 87 fluoroquinolones, beta-lactams (18,19) ). To assess this, the SH1000 mutants resistant to a 88 single aaRS inhibitor described above were used to independently select resistance to each 89 of the other two aaRS inhibitors at 4X MIC (Table 1) . In all cases, resistance to the second 90 aaRS inhibitor in these resistant mutants arose at a similar frequency to that observed for 91 selection of resistance to the same aaRS inhibitor in the fully susceptible SH1000 strain 92 (Table 1) . Thus, it is not difficult to select resistance to multiple aaRS inhibitors when the 93 bacterium is challenged with both agents sequentially rather than simultaneously. To further 94 evaluate the likelihood that strains resistant to multiple aaRS inhibitors could emerge, spread 95 and persist in the clinical setting, we examined whether the resulting resistance genotypes 96
were associated with a reduction in competitive fitness. Pair-wise competition assays were 97 conducted between resistant strains and SH1000 over 24 hours, following an established 98 protocol (14). Fitness costs were relatively modest for mutants resistant to a single aaRS 99 inhibitor (7-14%; Table 1), whilst a more considerable fitness cost was observed for 100 mutants concurrently resistant to two aaRS inhibitors (30-42%; Table 1 ). Thus, even when 101 mutants resistant to multi-targeted or multiple aaRS inhibitors do arise they incur fitness 102 burdens that may act to limit their clinical prevalence. 103
In conclusion, we have demonstrated that simultaneous targeting of two aaRS enzymes 104 overcomes the considerable resistance liabilities associated with inhibitors acting against a 105 single aaRS enzyme. Although mutants resistant to inhibitors of two aaRS enzymes can 106 become selected in a sequential manner, suggesting that such genotypes would emerge in 107 the clinical setting following prolonged selection, the double mutants are less fit and may be 108 compromised in respect of clinical spread or persistence. Our findings therefore support the 109 idea of discovering/developing aaRS inhibitor combinations or single agents that achieve 110 dual-targeting of aaRS enzymes. The latter would appear to represent a particularly 111 appealing prospect, and in view of the high degree of structural similarity shared by the 112 catalytic sites of subsets of the aaRS family (1), one that may prove feasible. 113
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